S2 Episode 2: How Bladder Cancer Immunostimulant N-803 May Shake Things Up
Artikel konnten nicht hinzugefügt werden
Der Titel konnte nicht zum Warenkorb hinzugefügt werden.
Der Titel konnte nicht zum Merkzettel hinzugefügt werden.
„Von Wunschzettel entfernen“ fehlgeschlagen.
„Podcast folgen“ fehlgeschlagen
„Podcast nicht mehr folgen“ fehlgeschlagen
S2 Episode 2: How Bladder Cancer Immunostimulant N-803 May Shake Things Up
-
Gesprochen von:
-
Von:
Über diesen Titel
Drs Cheryl Lee and Karim Chamie talk about efforts to develop nogapendekin alfa, aka N-803, and where it may fit into the shifting treatment paradigm for non-muscle invasive bladder cancer.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/987105). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
BCG-Unresponsive High-Grade Non-Muscle-Invasive Bladder Cancer: What Does the Practicing Urologist Need to Know? https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7997797/
Final Clinical Results of Pivotal Trial of IL-15rαfc Superagonist N-803 With BCG in BCG-Unresponsive CIS and Papillary Non-Muscle-Invasive Bladder Cancer (NMIBC) https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.4508
PK Sub-Study of QUILT-3.032 (CA ALT-803-01-16) and of QUILT-2.005 (CA ALT-803-01-14) https://www.clincosm.com/trial/pk-sub-quilt-3032-ca-alt-803-01-16-2005-14
